Amid Opioid Crisis, Insurers Restrict Pricey, Less Addictive PainkillersSeptember 18, 2017 |
Drug companies and doctors have been accused of fueling the opioid crisis, but some question whether insurers have played a role, too
Quick Read
Although vaccines typically take years to produce, test, and license, US health officials had voiced confidence that Zika would not be a difficult target, and some predicted that a vaccine could be made and fully tested, ready for FDA assessment, within two to three years. Others predicted a licensed Zika vaccine could be available sometime in 2020
Quick Read
How to Protect a Drug Patent?September 11, 2017 |
Sell it to a Native American Tribe. The drugmaker Allergan announced Friday that it had transferred its patents on a best-selling eye drug to the Saint Regis Mohawk Tribe in upstate New York — an unusual gambit to protect the drug from a patent dispute
Quick Read
This Shield of Patents Protects the World’s Best-Selling DrugSeptember 8, 2017 |
Over Humira’s lifetime, AbbVie has secured more than 100 patents to prevent anyone from attempting to copy the biologic, with $16 billion in annual sales
Quick Read
When doctors talk about a new leukemia drug from Novartis, they ooze enthusiasm, using words like “breakthrough,” “revolutionary” and “a watershed moment.” But when they think about how much the therapy is likely to cost, their tone turns alarmist. “It’s going to cost a fortune,” said Dr. Ivan Borrello at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore
Quick Read
Veteran Biopharma Exec Tries to Fund His Own ProductAugust 18, 2017 |
And sees firsthand how hard it is. Galvanized by his teenage son’s epilepsy diagnosis, Mayes started a new company to try to shepherd a promising inhaler technology for epilepsy through a key clinical trial
Quick Read
“A crippling problem.” “A total epidemic.” “A problem like nobody understands.” These are the words President Trump used to describe the opioid epidemic ravaging the country during a White House listening session in March
Quick Read
Faced with competition, some pharmaceutical companies are cutting deals with insurance companies to favor their brand-name products over cheaper generics. Insurers pay less, but sometimes consumers pay more. Adderall XR, a drug to treat attention-deficit hyperactivity disorder, is a case in point
Quick Read